Chronic Hepatitis B

The Chronic Hepatitis B pipeline: 34 tracked drugs, 7 approved for this indication.

7 approved / phase 45 Phase 39 Phase 26 Phase 1/26 Phase 11 preclinical / unstaged

Compare the share prices of listed companies in Chronic Hepatitis B →

Total attributable cost

$20.0B

$11,773/patient

Drug spend

Not yet sourced

How this is calculated ↗

any · US

The Chronic Hepatitis B pipeline

← all assets